Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer

被引:95
|
作者
Szabova, Ludmila [1 ]
Yin, Chaoying [4 ]
Bupp, Sujata [1 ]
Guerin, Theresa M. [1 ]
Schlomer, Jerome J. [1 ]
Householder, Deborah B. [1 ]
Baran, Maureen L. [1 ]
Yi, Ming [2 ]
Song, Yurong [3 ,4 ]
Sun, Wenping [2 ]
McDunn, Jonathan E. [5 ]
Martin, Philip L. [1 ]
Van Dyke, Terry [1 ,3 ,4 ]
Difilippantonio, Simone [1 ]
机构
[1] NCI Federick, Ctr Adv Preclin Res, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[2] NCI Federick, Adv Biomed Comp Ctr, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[3] NCI Frederick, Mouse Canc Genet Program, Frederick, MD USA
[4] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[5] Metabolon Inc, Durham, NC USA
关键词
MOUSE MODEL; CONDITIONAL INACTIVATION; FALLOPIAN-TUBE; PERITONEAL MESOTHELIOMA; PAPILLARY CARCINOMA; DISTANT METASTASES; MUTATIONS; INDUCTION; WOMEN; P130;
D O I
10.1158/0008-5472.CAN-11-3834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor suppression induced surface epithelial proliferation with progression to stage I carcinoma. Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC, and not with other intraperitoneal cancers. Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer. Cancer Res; 72(16); 4141-53. (C) 2012 AACR.
引用
收藏
页码:4141 / 4153
页数:13
相关论文
共 50 条
  • [1] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Gasowska-Bodnar, Agnieszka
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
  • [2] Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes
    Pietragalla, Antonella
    Arcieri, Martina
    Marchetti, Claudia
    Scambia, Giovanni
    Fagotti, Anna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1803 - 1810
  • [3] Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
    Paik, E. Sun
    Heo, Eun Jin
    Choi, Chel Hun
    Kim, Jae-Hoon
    Kim, Jae-Weon
    Kim, Yong-Man
    Park, Sang-Yoon
    Lee, Jeong-Won
    Kim, Jong-Won
    Kim, Byoung-Gie
    CANCER SCIENCE, 2021, 112 (12) : 5055 - 5067
  • [4] BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer
    Richau, Caroline Stahnke
    Scherer, Nicole de Miranda
    Matta, Bruna Palma
    de Armas, Elvismary Molina
    Moreira, Fabio Carvalho de Barros
    Bergmann, Anke
    Chaves, Claudia Bessa Pereira
    Boroni, Mariana
    dos Santos, Anna Claudia Evangelista
    Moreira, Miguel Angelo Martins
    CANCER MEDICINE, 2024, 13 (03):
  • [5] Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2
    Minion, Lindsey E.
    Dolinsky, Jill S.
    Chase, Dana M.
    Dunlop, Charles L.
    Chao, Elizabeth C.
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 86 - 92
  • [6] Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
    Kotsopoulos, Joanne
    Gronwald, Jacek
    McCuaig, Jeanna M.
    Karlan, Beth Y.
    Eisen, Andrea
    Tung, Nadine
    Bordeleau, Louise
    Senter, Leigha
    Eng, Charis
    Couch, Fergus
    Fruscio, Robert
    Weitzel, Jeffrey N.
    Olopade, Olufunmilayo
    Singer, Christian F.
    Pal, Tuya
    Foulkes, William D.
    Neuhausen, Susan L.
    Sun, Ping
    Lubinski, Jan
    Narod, Steven A.
    Huzarski, Tomasz
    Cybulski, Cezary
    Rosen, Barry
    Sweet, Kevin
    Zakalik, Dana
    Wood, Marie
    McKinnon, Wendy
    Elser, Christine
    Wiesner, Georgia
    Friedman, Eitan
    Meschino, Wendy
    Snyder, Carrie
    Metcalfe, Kelly
    Poll, Aletta
    Warner, Ellen
    Kim, Raymond
    Armel, Susan
    Demsky, Rochelle
    Ainsworth, Peter
    Steele, Linda
    Saal, Howard
    Serfas, Kim
    Panchal, Seema
    Cullinane, Carey A.
    Reilly, Robert E.
    Blum, Joanne L.
    Kwong, Ava
    Rayson, Daniel
    Ramon y Cajal, Teresa
    Dungan, Jeffrey
    GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 820 - 826
  • [7] Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
    Ferreyra, Yomali
    Rosas, Gina
    Cock-Rada, Alicia M.
    Araujo, Jhajaira
    Bravo, Leny
    Doimi, Franco
    Casas, Jhoysi
    Clavo, Maria de los Angeles
    Pinto, Joseph A.
    Belmar-Lopez, Carolina
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] BRCA1 and BRCA2 Genetic Testing in Breast and/or Ovarian Cancer Families in Iran
    Keshavarzi, Fatemeh
    Javadi, Gholam Reza
    Nafissi, Nahid
    Akbari, Mohammad Esmail
    Yassaee, Vahid Reza
    Farzad, Maryam Sharafi
    Zeinali, Sirous
    YAKHTEH, 2010, 12 (03): : 329 - 340
  • [9] Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2012, 83 (01) : 51 - 56
  • [10] Missense Polymorphisms in BRCA1 and BRCA2 and Risk of Breast and Ovarian Cancer
    Dombernowsky, Sarah Louise
    Weischer, Maren
    Freiberg, Jacob Johannes
    Bojesen, Stig Egil
    Tybjaerg-Hansen, Anne
    Nordestgaard, Borge Gronne
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (08) : 2339 - 2342